未登録の方はこちらから登録できます。
TEL．03-5812-5270
FAX．03-3831-0495
E-mail：info@spi-information.com
市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。
当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。
Innovations in Oral Solid Drug Delivery
経口固形製剤デリバリーの革新
このレポートは経口固形製剤のデリバリーシステムにおける革新を中心に、スタートアップ企業と大学の連携に重点を置いています。景気後退の影響、資金調達の制約、提携の機会について分析を行います。市場動態を把握し、さまざまな動向を分析します。例えば、2007-2012年にピークを迎えるブロックバスター医薬品の特許失効、過去数年間における第一世代経口固形製剤の特許消滅、パイプラインから生まれる新規化学物質の不足、などについて解説し、一部の疾患分野ではその市場規模が縮小していますが、こういった市場の現状に関連した新たな動きを分析します。新しい経口固形製剤デリバリーシステムの推進要因とそれを取り巻く課題を明らかにします。
主なテーマは、ペプチドやタンパク質の、静注から経口デリバリーへの移行です。売上、市場動向に言及し、競争環境について考察します。先発品の欠点として、例えば溶解性、バイオアベイラビリティ、効果の持続性などが低い、副作用が多い、安定性がない、経口投与後の吸収性が低い、苦味や不快な味、消化器吸収領域が狭い、患者間、患者内で吸収性にばらつきがある、といった問題を克服するために第一世代の経口固形製剤の組成変更というテーマが度々発生します。
高齢者人口の増大、長寿化に伴ない、経口固形製剤の開発は、アルツハイマー病、パーキンソン病、2型糖尿病と肥満、骨粗しょう症、がん、関節リウマチなどの高齢者の疾患の治療効果を高めることに重点が置かれています。これらの治療薬の多くは副作用があり、その投与条件や効果の持続性の問題、また注射剤しかないといった問題がその受容性を低下させる要因となっています。
目次
Table of Contents
- Executive summary
-
Market overview, dynamics and outlook
Advances in nanotechnology
Innovations in transitioning injectables to oral delivery
Advances in delayed & controlled release delivery
Advances in oral prodrug delivery
Advances in taste masking technologies
Innovative companies - Chapter 1 Market overview, dynamics and
-
outlookSummaryMarket overviewMarket dynamicsKey indicationsKey trendsNanomedicineTransitioning from injectablesProdrugsChrono releaseODTOSFFunding issuesPoor patient complianceInjectionsPoor absorbptionPediatricGeriatricSolubility and variable absorptionReduction of side effect profilesNon-invasive protein deliveryTransition from injectables to preferred route of oral drug deliveryDirected delivery and delayed delivery to reduce side effect potentialFormulation technologies for poorly soluble compoundsTaste masking for pediatric and geriatric formulationsCompetitive landscape
Conclusions and key findings - Chapter 2 Advances in nanotechnology
-
Summary
Introduction
Nanotechnology platforms with application for oral drug deliverySelf-Emulsifying Controlled Release Tablet system (SECRET)TechnologyApplicationBiotransport nanomedicine technologyTechnologyApplicationNanobodiesTechnologyApplicationNanoDel nanoparticlesTechnologyApplicationP-gpMaskTechnologyApplicationNanoDRY and NanoCOATTechnologyApplicationSolumerTechnologyApplicationNanocellsTechnologyApplicationPolymeric Nano-Delivery System (PNDS)TechnologyApplicationFluidCrystal NP Oral nanoparticlesTechnologyApplicationCaP Technology and BioOralTechnologyApplicationNab Technology and ProtospheresTechnologyApplicationNanoCrystal TechnologyTechnologyApplicationBioralTechnologyApplicationSqualenoyl nanoparticlesNanoMegaNOD Pharmaceutical - Chapter 3 Innovations in transitioning injectables to oral delivery
-
Summary
IntroductionDriversPatient acceptability & complianceCost savingsRestraintsAdvances in injectable deliveryChallenges of oral drug delivery
Technologies used in oral drug delivery of peptides and proteinsEnzyme inhibitorsPermeation enhancersMucoadhesivesEncapsulation technologiesM-cell targetingCompetitive landscape
Osteoporosis and other bone related conditionsCalcitoninCurrent therapies & market landscapeOral products in developmentParathyroid hormoneCurrent therapies & market landscapeOral products in developmentCombined oral calcitonin and PTH approachesBisphosphonatesCurrent therapies & market landscapeNovel oral products in developmentDiabetes and other metabolic diseasesOral insulinOramed PharmaceuticalsBiocon LtdEmisphere TechnologiesDiabetologyNOD PharmaceuticalsAccess PharmaceuticalsNanoMega Medical CorporationBiodel IncMetabolic Pharmaceuticals LtdGlucagon-like peptide-1 (GLP-1) and GLP-1 analogsOral GLP-1 & GLP-1 analogsObesityAlzheimer's and other CNS conditionsOligotropinEndometriosis and prostate cancerLeuprolideCardiovascularAngiotensin analogsInnovative approaches to oral vaccine developmentMucosis B.V.Plug-and-Play TechnologyGEM ParticlesMimopathOndek Pty LtdHelicobacter pylori Platform Technology (HPPT)InfexionKancerImmune SolutionsLiporale - Chapter 4 Advances in delayed & controlled release delivery
-
Summary
Introduction
Types of controlled release systemsSustained releasePulsatile releaseModified drug deliveryFast disintegrating technologiesPediatric formulations - ODTSchizophrenia and bipolar disorder - ODTAlzheimer's disease - ODTParkinson's disease - ODTAnxiety and panic disorder - ODTMajor depressive disorder - ODTNausea and vomiting - ODTMigraine - ODTAutism - ODTGERD and gastroparesis - ODTRelease control mechanismsZero orderCongestive heart failure and hypertension - sustained releasePain - sustained releaseADHD - sustained releaseMultiple sclerosis - sustained releaseMuscle relaxant - sustained releaseParkinson's disease - sustained releaseDepression - sustained releaseBinaryDiabetes type 2 - combination productsHypertension - combination productsOtherBiphasic release of drugsAsthma - biphasic releasePain - biphasic releaseADHD - biphasic releaseHypertension - biphasic releasePositionedParkinson's disease - positioned biphasic releaseInsomnia - positioned biphasic releaseSpasticity - positioned biphasic releaseGERD - positioned releaseDiabetes type 2 - positioned extended releaseHot flashes - positioned extended releasePain - positioned extended releaseGERD - positioned extended releaseParkinson's disease - positioned extended releaseOthersAcceleratedTimedMultiple pulseTargeted delivery to the colonUlcerative colitis, gastroenteritis - targeted colon releaseNutraceutical - targeted colon releasePolysaccharide colon selectiveCOLAL technologyChrono releaseRheumatoid arthritis - chrono releaseSevere asthma - chrono releasePolymyalgia rheumatica - chrono releaseInsomnia - chrono releaseSublingual formulationsFormulations to counteract opiate or psychostimulant abuseTrigger-LockOraGuardNanoDRY and NanoCOATORADURAversion TechnologyEgalet ADPREMDETERxAvertStrategic alliances - Chapter 5 Advances in oral prodrug delivery
-
Summary
IntroductionClassification based on site of conversion to active drugClassification based on chemical linkages or promoiety/carriers that attach to the active drugClassification based on the deficiency in the active drugClassification based on carrier-linked or bioprecursor categoriesApplications of prodrug technologyReducing side effect profileIntroducing site specificity - colonTaste masking applicationsMarketed products and market shareAntiviral prodrugsOseltamivirValaciclovirValganciclovirFamciclovirAnticancer prodrugsTS-1Cardiovascular prodrugsACE inhibitorsAngiotensin II receptor antagonistsHMG Co A reductase inhibitorsRespiratory prodrugsBambuterolCNS prodrugsLisdexamfetamineLate and early stage development product formulationsImproving oral bioavailability/reducing toxicity of older marketed injectable drugsAntiviral prodrugsCidofovirVidarabineZanamivirAnticancer prodrugsTriciribineCamptothecinGemcitabineDocetaxelMethotrexateAimpilaFAP activated ultra-smart prodrug cytotoxic agentCNS prodrugsGabapentin encarbilArbaclofen placarbilLevodopaLY2140023ARX-111 and ARX-211Antibiotic prodrugsSulopenem etzadroxilTorezolid phosphateOthersTranexamic acidABS-15 and ABS-16 - Chapter 6 Advances in taste masking
-
technologies
Summary
Introduction
Taste masking strategiesFlavor enhancersLimiting solubility of the drugPolymer coatingComplexation with ion exchange resinsLiposomesChemical modificationsMultiple emulsionsMass extrusion method (dispersion coating)Anesthetic agentsOther agentsOrally disintegrating tablets
ODT technologiesCapricorn Pharma Inc.RDT (rapidly dispersible tablet)RMB (Rapid Melt Beads)DAB (Disperse Beads)KORCAPRapidMeltKORKOAT beadsEgaletParvuletEthypharmFlashtab and T-maskEurand BVAdvaTab, Microcaps & LiquitardSupernusForTe BVFlavoRiTeNOWGlycologicsBeta-limit dextrin (BLD)Alginate-Pectin-Starch (APS)ADD Technologies LtdMicroPxCambrexCamouflage DDTCIMAOraSolvDuraSolvLyocOTS and OraVescent transmucosal tabletOraGuardAlte BioSciencesOralezeOral soluble filmsLabtec GmbHRapidFilmMonoSol RxPharmFilmPharmFilm and NanocellUniversity research into new taste masking technologiesBharati Vidyapeeth Deemed UniversityUniversity Institute of Chemical TechnologyPrin. K.M. Kundanani College of Pharmacy - Chapter 7 Innovative companies
-
Summary
Introduction
Proxima Concepts Ltd LaboratoryOverviewTechnology platformsAxcessVaxcineMozaicLexiconBone Medical LtdOverviewProduct development pipelineDiabetologyOverviewProduct development pipelineKancer LtdOverviewInfexionOverviewStrategyNanolymf LtdOverviewTechnology platformP-gpMaskStrategyPatents portfolio related to technologiesChimerixOverviewTechnology platformProLipTagProduct development pipelineStrategyMucosis B. V.OverviewTechnology platformsPlug-and-Play TechnologyGEM ParticlesMimopathProduct development pipelineResearch and development collaborationsStrategyOndek Pty LtdOverviewTechnology platformHelicobacter pylori Platform Technology (HPPT)Product development pipelineStrategyPatent portfolio relating to technologiesMBC Pharma IncOverviewTechnology platformsBisphosphonate B6 TechnologyProduct development pipelineResearch and development collaborationsStrategyPatents portfolio related to technologiesOraDel Medical LtdOverviewTechnology platformCPL - Chitosan-coated proliposome technologyPatent portfolio related to technologiesImmuPharma plcOverviewTechnology platformsPeptide-to-Drug Converting Technology (PDCT)Product development pipelineStrategyAccess PharmaceuticalsOverviewTechnology platformsCobalamin-Mediated Oral DeliveryProduct development pipelineStrategyActoGeniXTechnology platformsTopActProduct development pipelineResearch and development collaborationsStrategyBiocon LtdOverviewProduct development pipelineChiasma (Israel) LtdOverviewTechnology platformsTransient Permeability Enhancer (TPE)Product development pipelineStrategyPatent portfolio related to technologyEmisphereOverviewTechnology platformsEligen TechnologyProduct development pipelineStrategyKytogenicsOverviewTechnology platformsTight Junction Opener Technology (TIJO)Product development pipelineStrategyMerrion PharmaceuticalsOverviewTechnology platformsGIPETGIRESProduct development pipelineResearch and development collaborations 2006-2009StrategyPatent portfolio relating to technologiesNOD Pharmaceuticals, Inc.OverviewTechnology platformsNOD TechnologyProduct development pipelineStrategyPatents portfolio related to technologyOramed PharmaceuticalsOverviewTechnology platformProduct development pipelineStrategyPatents portfolio related to oral delivery technologySamyang CorporationTechnology platformsSY-CSDSODTPatent portfolio relating to technologiesUnigeneOverviewTechnology platformsEnteripepProduct development pipelineResearch and development collaborations 2007-2009StrategyPatent portfolio relating to technologies - Chapter 8 Appendix
-
Primary research methodologyMedTRACK platform identificationIMS data
Glossary
Index
List of Figures
Figure 1.1: Market share of oral solid dose forms, 2008
Figure 1.2: Prodrugs, nanomedicines & peptides targeting specific indications
Figure 1.3: Formulations targeting specific indications
Figure 2.4: Advantages of nanotechnology for oral solid dose drug delivery
Figure 3.5: Mechanisms of drug transport across the intestinal epithelium
Figure 3.6: Market share of leading calcitonin products, 2008
Figure 4.7: Approaches to targeted colon delivery
Figure 5.8: Influenza antivirals market share (%) in the US, 2008
Figure 6.9: Oral soluble film products in the OTC sector
List of Tables
Table 2.1: US sales for opioid dependence ($m), 2008
Table 2.2: US sales for fenofibrate ($m), 2008
Table 2.3: Oral nanomedicines in development
Table 3.4: Global sales for calcitonin ($m), 2008
Table 3.5: Oral calcitonin products in development
Table 3.6: Major market sales for Forteo and Preotact ($m), 2008
Table 3.7: Oral PTH and analog products in development
Table 3.8: Global sales for bisphosphonates ($bn), 2008
Table 3.9: Oral bisphosphonates products in development
Table 3.10: Oral insulins in development
Table 3.11: Byetta (exenatide) sales in major markets ($m), 2008
Table 3.12: Oral GLP-1 and GLP-1 analogs in development
Table 3.13: Other oral peptide/protein products under development
Table 4.14: US sales for anti-Alzheimer's disease products ($m), 2008
Table 4.15: US sales for leading antidepressant products in N6A9 ($m), 2008
Table 4.16: US sales for SSRI antidepressants ($m), 2008
Table 4.17: US sales for leading beta-blockers plain ($m), 2008
Table 4.18: US sales for leading muscle relaxants ($m), 2008
Table 4.19: US sales for SNRI antidepressant products ($m), 2008
Table 4.20: Formulations to counter opiate/psychostimulant abuse
Table 5.21: Prodrug classification based on site of conversion to active drug
Table 5.22: Major market sales for Valtrex (valaciclovir) ($m), 2008
Table 5.23: Major market sales for Valcyte (valganciclovir) ($m), 2008
Table 5.24: US sales for herpes antivirals ($m), 2008
Table 5.25: Major market sales for Xeloda (capecitabine) ($m), 2008
Table 5.26: Leading antimetabolite anticancer drugs in the US ($m), 2008
Table 5.27: Leading antimetabolite anticancer drugs in Japan ($m), 2008
Table 5.28: US sales for leading psychostimulant drugs ($m), 2008
Table 5.29: Major market sales for Vistide (cidofovir) ($m), 2008
Table 5.30: Major market sales for Hycamtin (topotecan) ($m), 2008
Table 5.31: Major market sales for Gemzar (gemcitabine) ($m), 2008
Table 5.32: US sales of vinca alkaloid cancer agents ($m), 2008
Table 5.33: Major market sales for Taxotere (docetaxel) ($m), 2008
Table 5.34: Major market sales for methotrexate ($m), 2008
Table 5.35: US sales for leading anti-Parkinson's preparations ($m), 2008
Table 5.36: Major market sales for Zyvox (linezolid) ($m), 2008
Table 6.37: US sales for leading antiepileptic products ($m), 2008
Table 6.38: US sales for antismoking products ($m), 2008
Table 7.39: Bone Medical product development pipeline
Table 7.40: Diabetology product development pipeline
Table 7.41: Chimerix product development pipeline
Table 7.42: Ondek product development pipeline
Table 7.43: MBC Pharma product development pipeline
Table 7.44: MBC Pharma R&D collaborations, 2005- 09
Table 7.45: ImmuPharma product development pipeline
Table 7.46: Access product development pipeline
Table 7.47: Access R&D collaborations, 2003-09
Table 7.48: ActoGeniX product development pipeline
Table 7.49: ActoGeniX R&D collaborations, 2005-09
Table 7.50: Biocon Ltd product development pipeline
Table 7.51: Chiasma product development pipeline
Table 7.52: Emisphere product development pipeline
Table 7.53: Emisphere R&D collaborations, 2005-09
Table 7.54: Kytogenics product development pipeline
Table 7.55: Merrion product development pipeline
Table 7.56: Merrion R&D collaborations
Table 7.57: NOD Pharmaceuticals product development pipeline
Table 7.58: Oramed Pharmaceuticals product development pipeline
Table 7.59: Unigene product development pipeline
Table 7.60: Unigene R&D collaborations
発刊日
2010/04/01
体裁
PDF / 369ページ
販売価格
3,835USD
発行
Business Insights Ltd.
備考
※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。
関連カテゴリ
購入・お問い合わせ
